These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 11740219)

  • 21. Integration of temperature-controlled requirements into pharmacy practice.
    Ziance R; Chandler C; Bishara RH
    J Am Pharm Assoc (2003); 2009; 49(3):e61-7; quiz e68-9. PubMed ID: 19443313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice.
    Holló G; Topouzis F; Fechtner RD
    Expert Opin Pharmacother; 2014 Aug; 15(12):1737-47. PubMed ID: 24998246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Influence on ocular surface and intraocular pressure of switching from preservative-containing to preservative-free carteolol hydrochloride ophthalmic solution].
    Chikama T; Araie M; Nishida T
    Nippon Ganka Gakkai Zasshi; 2013 May; 117(5):419-26. PubMed ID: 23855234
    [No Abstract]   [Full Text] [Related]  

  • 24. Evaluation of different preparation methods for a preservative free triamcinolone acetonide preparation for intravitreal administration: a validated stability indicating HPLC-method.
    Korodi T; Lachmann B; Kopelent-Frank H
    Pharmazie; 2010 Dec; 65(12):860-6. PubMed ID: 21284253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective, Randomized, Single Masked, Parallel Study Exploring the Effects of a Preservative-Free Ophthalmic Solution Containing Hyaluronic Acid 0.4% and Taurine 0.5% on the Ocular Surface of Glaucoma Patients Under Multiple Long-Term Topical Hypotensive Therapy.
    Roberti G; Agnifili L; Berardo F; Riva I; Figus M; Manni G; Quaranta L; Oddone F
    Adv Ther; 2018 May; 35(5):686-696. PubMed ID: 29687335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of additives and storage temperature on physicochemical and microbiological properties of eye drops containing cefazolin.
    Kodym A; Zawisza T; Buźka K; Kukuła H
    Acta Pol Pharm; 2006; 63(3):225-34. PubMed ID: 20085229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Preservative substances - the daily dose of benzalkonium chloride in glaucoma treatment from the patients point of view].
    Výborný P; Sičáková S; Veselá Flórová Z
    Cesk Slov Oftalmol; 2014 Jun; 70(3):95-7. PubMed ID: 25032794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medical therapy cost considerations for glaucoma.
    Fiscella RG; Green A; Patuszynski DH; Wilensky J
    Am J Ophthalmol; 2003 Jul; 136(1):18-25. PubMed ID: 12834665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preservative-free versus preserved latanoprost eye drops in patients with open-angle glaucoma or ocular hypertension.
    Aptel F; Choudhry R; Stalmans I
    Curr Med Res Opin; 2016 Aug; 32(8):1457-63. PubMed ID: 27310103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Preservative-free glaucoma treatment : Selection of the correct treatment in 1 min].
    Pfennigsdorf S; Eschstruth P
    Ophthalmologe; 2016 May; 113(5):409-15. PubMed ID: 26563361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives.
    Ramli N; Supramaniam G; Samsudin A; Juana A; Zahari M; Choo MM
    Optom Vis Sci; 2015 Sep; 92(9):e222-6. PubMed ID: 25730335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension.
    Erb C; Lanzl I; Seidova SF; Kimmich F
    Adv Ther; 2011 Jul; 28(7):575-85. PubMed ID: 21725844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Corneal sensitivity in patients treated medically for glaucoma or ocular hypertension].
    Van Went C; Alalwani H; Brasnu E; Pham J; Hamard P; Baudouin C; Labbé A
    J Fr Ophtalmol; 2011 Dec; 34(10):684-90. PubMed ID: 22093372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid and selective removal of preservative from ophthalmic formulations during eyedrops instillation.
    Hsu KH; Chauhan A
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):30-8. PubMed ID: 26459089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications.
    Lazreg S; Merad Z; Nouri MT; Garout R; Derdour A; Ghroud N; Kherroubi R; Meziane M; Belkacem S; Ouhadj O; Baudouin C; Tiar M
    J Fr Ophtalmol; 2018 Dec; 41(10):945-954. PubMed ID: 30477719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology.
    Martone G; Frezzotti P; Tosi GM; Traversi C; Mittica V; Malandrini A; Pichierri P; Balestrazzi A; Motolese PA; Motolese I; Motolese E
    Am J Ophthalmol; 2009 Apr; 147(4):725-735.e1. PubMed ID: 19181302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and tolerability of preservative-free eye drops containing a fixed combination of dorzolamide and timolol in glaucoma patients.
    Renieri G; Führer K; Scheithe K; Lorenz K; Pfeiffer N; Thieme H
    J Ocul Pharmacol Ther; 2010 Dec; 26(6):597-603. PubMed ID: 20977366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma.
    Baudouin C
    Acta Ophthalmol; 2008 Nov; 86(7):716-26. PubMed ID: 18537937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ophthalmic preservatives: focus on polyquaternium-1.
    Rolando M; Crider JY; Kahook MY
    Expert Opin Drug Deliv; 2011 Nov; 8(11):1425-38. PubMed ID: 21905766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cost-effectivity analysis of the most used antiglaucoma drugs].
    Galindo-Ferreiro A; Sánchez-Tocino H; Fernández-Muñoz M; Iglesias Cortiñas D
    Arch Soc Esp Oftalmol; 2004 Aug; 79(8):379-84. PubMed ID: 15306964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.